Condition (MeSH)
Cardiomyopathy, Hypertrophic, Familial
ClinicalTrials.gov lists 7 trials for Cardiomyopathy, Hypertrophic, Familial or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
7 of the 7 trials are tagged with Cardiomyopathy, Hypertrophic, Familial itself; the rest are tagged with a narrower condition beneath it.
When did Cardiomyopathy, Hypertrophic, Familial trials start? (7)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1/2
- Phase 2
- Phase 2/3
- Observational
Top of scale: 1
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2023 | 1 |
| 2021 | 1 |
| 2016 | 1 |
| 2015 | 1 |
| 2014 | 1 |
| 2013 | 1 |
| 1999 | 1 |
No forecast is made for this condition: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 7 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Cardiomyopathy, Hypertrophic, Familial trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1/2 | 1 |
| Phase 2 | 1 |
| Phase 2/3 | 1 |
| Observational | 4 |
How many Cardiomyopathy, Hypertrophic, Familial trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 2 |
| Enrolling by invitation | 1 |
| Completed | 2 |
| Terminated | 2 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Cardiomyopathy, Hypertrophic, Familial trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Gilead Sciences | 1 |
| Heart Metabolics Limited | 1 |
| National Heart, Lung, and Blood Institute (NHLBI) | 1 |
| Tenaya Therapeutics | 1 |
Which serious adverse events do Cardiomyopathy, Hypertrophic, Familial trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| CHEST PAIN | 4 | 1 |
| ATRIAL FIBRILLATION | 3 | 1 |
| VENTRICULAR TACHYCARDIA | 3 | 1 |
| CARDIAC FAILURE CONGESTIVE | 2 | 1 |
| DEVICE RELATED INFECTION | 2 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Cardiomyopathy, Hypertrophic, Familial? (13)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Hypertrophic Cardiomyopathy: Clinical Update. | JACC. Heart failure | 2018 | Yes |
| Telomere shortening is a hallmark of genetic cardiomyopathies. | Proceedings of the National Academy of Sciences of the United States of America | 2018 | Yes |
| α-Galactosidase A Genotype N215S Induces a Specific Cardiac Variant of Fabry Disease. | Circulation. Cardiovascular genetics | 2017 | Yes |
| Advances in medical treatment of hypertrophic cardiomyopathy. | Journal of cardiology | 2014 | Yes |
| Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence. | European heart journal | 2012 | Yes |
Showing 5 of 13 publications.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Rare familial disorder with hypertrophic cardiomyopathy | 99739 | Exact | Orphadata Science knowledge files, Product 1 |
| Rare familial disorder with hypertrophic cardiomyopathy | 99739 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.